1. Home
  2. STC vs DFTX Comparison

STC vs DFTX Comparison

Compare STC & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stewart Information Services Corporation

STC

Stewart Information Services Corporation

HOLD

Current Price

$61.02

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.39

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
STC
DFTX
Founded
1893
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
STC
DFTX
Price
$61.02
$20.39
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$81.33
$40.25
AVG Volume (30 Days)
187.6K
1.6M
Earning Date
04-22-2026
05-04-2026
Dividend Yield
3.42%
N/A
EPS Growth
55.17
N/A
EPS
4.05
N/A
Revenue
$2,921,636,000.00
N/A
Revenue This Year
$13.62
N/A
Revenue Next Year
$7.13
N/A
P/E Ratio
$15.16
N/A
Revenue Growth
17.32
N/A
52 Week Low
$56.39
$14.62
52 Week High
$78.61
$21.10

Technical Indicators

Market Signals
Indicator
STC
DFTX
Relative Strength Index (RSI) 44.63 63.24
Support Level $60.08 $16.41
Resistance Level $71.84 N/A
Average True Range (ATR) 1.92 1.09
MACD 0.29 0.23
Stochastic Oscillator 50.00 82.47

Price Performance

Historical Comparison
STC
DFTX

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: